Skip to main content
Premium Trial:

Request an Annual Quote

University of Sydney Wins A$1.4M Grant, Teams With Allelica on Cardiac Polygenic Risk Scores

NEW YORK – Researchers at the University of Sydney said Monday that they have won a grant worth A$1.4 million ($1.1 million) from Australia's National Health and Medical Research Council and will work with Allelica to apply polygenic risk scores for coronary artery disease prevention.

The grant money supplements the A$2 million that project leaders have received from industry partners, according to the university.

With the funding, a multidisciplinary team led by Gemma Figtree, chair of the University of Sydney's Cardiovascular Initiative, will develop strategies to prevent heart disease by applying polygenic risk scores in primary care settings.

Figtree and colleagues will test and validate Allelica's polygenic risk score technology in clinical practice, with hopes of integrating the scores into routine clinical practice, a stated goal of New York-based Allelica. Participants in the study will receive their results back through the Allelica platform.

"The first step in reducing the impact of preventable chronic disease is to identify people at high risk," Allelica CEO Giordano Bottà said in a statement. "In the case of coronary artery disease, the root of the problem is the dangerous lack of accuracy in most risk classification models."

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.